Web04. jan 2024. · ANDOVER, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform... Web01. mar 2024. · ONCR-177 is an engineered recombinant oncolytic herpes simplex virus (HSV) with complementary safety mechanisms, including tissue-specific miRNA attenuation and mutant UL37 to inhibit replication, neuropathic activity, and latency in normal cells.
Senior Scientist, Analytical Development Job in Andover, MA at Oncorus
Web06. mar 2024. · View Jacqueline Gursha's business profile as Principal Associate Scientist at Oncorus. Find contact's direct phone number, email address, work history, and more. Web30. nov 2024. · Item 7.01 Regulation FD Disclosure. On November 30, 2024, Oncorus, Inc. (the "Company") issued a press release announcing the reprioritization of its product pipeline to focus on its lead self-amplifying viral RNA ("vRNA") immunotherapy product candidate, ONCR-021, along with the discontinuation of its Phase 1 clinical trial of ONCR … gang beast action figures
SEC Filing • Oncorus, Inc
Web28. feb 2024. · About Oncorus Oncorus is a biopharmaceutical company located in Andover, MA, focused on developing next-generation, systemically active viral immunotherapies to transform outcomes for cancer patients. At Oncorus, our mission is to enable more patients to respond to this revolutionary approach of harnessing the body's … Web14. mar 2024. · Oncorus, Inc. (the "Company") continues to monitor the situation involving Silicon Valley Bank ("SVB") and the actions taken by the California Department of Financial Protection and Innovation and the Federal Deposit Insurance Corporation. WebInquiries: General information: [email protected]. Careers: [email protected]. Partnering: [email protected]. We are pursuing a viral immunotherapy, ONCR-719, to specifically target brain … black lab head cover